<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932646</url>
  </required_header>
  <id_info>
    <org_study_id>1222.25</org_study_id>
    <nct_id>NCT00932646</nct_id>
  </id_info>
  <brief_title>Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The study is intended to characterize the lung function profile of BI1744 in COPD patients
      where patients will perform pulmonary function tests at regular intervals for 24 hours at the
      end of a 6 week treatment period. Each patient will receive all four treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to am dose on the first day of treatment (baseline) and -30 min (zero time), 30 min, 60 min, 2 hour (h) , 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min relative to am dose after six weeks of treatment</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 Area Under Curve 12-24h (AUC 12-24h) Response After Six Weeks of Treatment</measure>
    <time_frame>1 h and 10 min prior to am dose on the first day of treatment (baseline) and 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 h (AUC 0-24h) Response After Six Weeks of Treatment</measure>
    <time_frame>1 h and 10 min prior to am dose on the first day of the treatment (baseline) and -30 min, 30 min, 60 min, 2h, 3h, 4h, 6h, 8h, 10h, 11 hr 50 min,12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment.</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response After Six Weeks of Treatment</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -30 min, 30 min, 60 min, 2 h , 3 h, relative to am dose after six weeks of treatment</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-3h was calculated from 0-3hours post-dose using the trapezoidal rule, divided by the observation time (3 h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (0-3h) Response</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak values were obtained within 0 - 3 hours after the last am dose after six weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to am dose on the first day of treatment (baseline) and -30 min (zero time), 30 min, 60 min, 2 hour (h) , 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min relative to am dose after six weeks of treatment</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</measure>
    <time_frame>1 h and 10 min prior to am dose on the first day of treatment (baseline) and 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</measure>
    <time_frame>1 h and 10 min prior to am dose on the first day of treatment (baseline) and -30 min, 30 min, 60 min, 2h, 3h, 4h, 6h, 8h, 10h, 11 hr 50 min,12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment.</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC (0-3h) Response</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC was obtained within 0 - 3 hours after the last am dose of study drug after 6 weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>BI1744 (Olodaterol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Dose once Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1744 (Olodaterol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose once Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Foradil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 mcg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 (Olodaterol) Low Dose</intervention_name>
    <description>BI1744 Respimat low dose once daily and placebo Foradil</description>
    <arm_group_label>BI 1744 (Olodaterol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 (Olodaterol) Medium Dose</intervention_name>
    <description>BI1744 Respimat medium dose once daily and placebo Foradil</description>
    <arm_group_label>BI1744 (Olodaterol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Respimat once daily and placebo Foradil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foradil</intervention_name>
    <description>12 mcg twice daily and placebo Respimat</description>
    <arm_group_label>Foradil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing to participate with confirmed diagnosis of COPD

          -  40 years of age or older

          -  having a 10 pack year smoking history

          -  able to perform serial pulmonary function tests

          -  able to use both a DPI and Respimat device

        Exclusion Criteria:

        Significant other disease

          -  clinically relevant abnormal hematology, chemistry, or urinalysis

          -  history of asthma

          -  diagnosis of thyrotoxicosis

          -  paroxysmal tachycardia related to beta agonists

          -  history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure
             within 1 year

          -  active tuberculosis, cystic fibrosis, clinically evident bronchiectasis

          -  significant alcohol or drug use

          -  pulmonary resection

          -  taking oral beta adrenergics

          -  taking unstable oral steroids

          -  daytime oxygen

          -  enrolled in rehabilitation program

          -  enrolled in another study or taking investigational products

          -  pregnant or nursing women, women of child bearing potential not willing to use two
             methods of birth control

          -  those who are not willing to comply with pulmonary medication washouts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.25.25009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.25.25013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>May 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2014</results_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomised, double-blind, double dummy, placebo- and active-controlled, 4 way crossover trial. The duration of each treatment period was 6 weeks with a 14 day washout period between treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo / Olo 5mcg / Olo 10mcg / Foradil 12mcg</title>
          <description>Patients were administered placebo in the first period, Olodaterol 5 mcg qd in the second period, Olodaterol 10 mcg qd in the third period and Foradil 12 mcg bid in the fourth period. Olodaterol was administered via the Respimat inhaler, Foradil was administered via the Aerolizer inhaler.</description>
        </group>
        <group group_id="P2">
          <title>Olo 5mcg / Foradil 12mcg / Placebo / Olo 10mcg</title>
          <description>Patients were administered Olodaterol 5mcg qd in the first period, Foradil 12 mcg bid in the second period, placebo in the third period and Olodaterol 10 mcg qd in the fourth period. Olodaterol was administered via the Respimat inhaler, Foradil was administered via the Aerolizer inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Olo 10mcg / Placebo / Foradil 12mcg / Olo 5mcg</title>
          <description>Patients were administered Olodaterol 10 mcg qd in the first period, placebo in the second period, Foradil 12 mcg bid in the third period and Olodaterol 5 mcg qd in the fourth period. Olodaterol was administered via the Respimat inhaler, Foradil was administered via the Aerolizer inhaler.</description>
        </group>
        <group group_id="P4">
          <title>Foradil 12mcg / Olo 10mcg / Olo 5mcg / Placebo</title>
          <description>Patients were administered Foradil 12 mcg bid in the first period, Olodaterol 10 mcg qd in the second period, Olodaterol 5 mcg qd in the third period and placebo in the fourth period. Olodaterol was administered via the Respimat inhaler, Foradil was administered via the Aerolizer inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set, i.e. all treated patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Total</title>
          <description>Total number of patients treated in the study. This was a randomised, double-blind, double dummy, placebo- and active-controlled, 4 way crossover trial. 99 patients were assigned randomly to one of 4 treatment sequences in which they received each of 4 treatments, two doses (5 microgram (mcg) or 10 mcg) of Olodaterol (Olo) once daily (qd) delivered via the Respimat inhaler or Foradil (Form) 12 mcg twice daily (bid) delivered via the Aerolizer inhaler or equivalent placebo delivered by Respimat Inhaler or Aerolizer Inhaler. The duration of each treatment period was 6 weeks with a 14 day washout period between treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to am dose on the first day of treatment (baseline) and -30 min (zero time), 30 min, 60 min, 2 hour (h) , 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min relative to am dose after six weeks of treatment</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients with the baseline (pre-dose) date and any evaluable post-dosing data for the first co-primary endpoint FEV1AUC 0-12h.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler or Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients with the baseline (pre-dose) date and any evaluable post-dosing data for the first co-primary endpoint FEV1AUC 0-12h.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.024"/>
                    <measurement group_id="O2" value="0.150" spread="0.024"/>
                    <measurement group_id="O3" value="0.152" spread="0.024"/>
                    <measurement group_id="O4" value="0.136" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.140</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.124</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 h (AUC 0-24h) Response After Six Weeks of Treatment</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
        <time_frame>1 h and 10 min prior to am dose on the first day of the treatment (baseline) and -30 min, 30 min, 60 min, 2h, 3h, 4h, 6h, 8h, 10h, 11 hr 50 min,12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 h (AUC 0-24h) Response After Six Weeks of Treatment</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="0.024"/>
                    <measurement group_id="O2" value="0.110" spread="0.024"/>
                    <measurement group_id="O3" value="0.112" spread="0.024"/>
                    <measurement group_id="O4" value="0.121" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.145</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.179</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response After Six Weeks of Treatment</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-3h was calculated from 0-3hours post-dose using the trapezoidal rule, divided by the observation time (3 h) to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -30 min, 30 min, 60 min, 2 h , 3 h, relative to am dose after six weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response After Six Weeks of Treatment</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 0-3h was calculated from 0-3hours post-dose using the trapezoidal rule, divided by the observation time (3 h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.024"/>
                    <measurement group_id="O2" value="0.190" spread="0.025"/>
                    <measurement group_id="O3" value="0.202" spread="0.025"/>
                    <measurement group_id="O4" value="0.217" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.186</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.149</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.198</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.162</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.213</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.176</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (0-3h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak values were obtained within 0 - 3 hours after the last am dose after six weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (0-3h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak values were obtained within 0 - 3 hours after the last am dose after six weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" spread="0.026"/>
                    <measurement group_id="O2" value="0.268" spread="0.026"/>
                    <measurement group_id="O3" value="0.273" spread="0.026"/>
                    <measurement group_id="O4" value="0.293" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>0.230</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.197</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.158</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.217</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.178</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.030"/>
                    <measurement group_id="O2" value="0.109" spread="0.030"/>
                    <measurement group_id="O3" value="0.115" spread="0.030"/>
                    <measurement group_id="O4" value="0.093" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.155</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to am dose on the first day of treatment (baseline) and -30 min (zero time), 30 min, 60 min, 2 hour (h) , 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min relative to am dose after six weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.032" spread="0.040"/>
                    <measurement group_id="O2" value="0.219" spread="0.040"/>
                    <measurement group_id="O3" value="0.214" spread="0.040"/>
                    <measurement group_id="O4" value="0.203" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.251</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.195</ci_lower_limit>
            <ci_upper_limit>0.306</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.246</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.190</ci_lower_limit>
            <ci_upper_limit>0.302</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.235</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.179</ci_lower_limit>
            <ci_upper_limit>0.291</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 h and 10 min prior to am dose on the first day of treatment (baseline) and 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.078" spread="0.041"/>
                    <measurement group_id="O2" value="0.083" spread="0.041"/>
                    <measurement group_id="O3" value="0.079" spread="0.041"/>
                    <measurement group_id="O4" value="0.144" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.223</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.162</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 h and 10 min prior to am dose on the first day of treatment (baseline) and -30 min, 30 min, 60 min, 2h, 3h, 4h, 6h, 8h, 10h, 11 hr 50 min,12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment.</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.039"/>
                    <measurement group_id="O2" value="0.151" spread="0.039"/>
                    <measurement group_id="O3" value="0.147" spread="0.039"/>
                    <measurement group_id="O4" value="0.174" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.206</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.155</ci_lower_limit>
            <ci_upper_limit>0.258</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.202</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.229</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.176</ci_lower_limit>
            <ci_upper_limit>0.281</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC (0-3h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC was obtained within 0 - 3 hours after the last am dose of study drug after 6 weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC (0-3h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC was obtained within 0 - 3 hours after the last am dose of study drug after 6 weeks of treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.138" spread="0.043"/>
                    <measurement group_id="O2" value="0.436" spread="0.043"/>
                    <measurement group_id="O3" value="0.440" spread="0.043"/>
                    <measurement group_id="O4" value="0.475" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.299</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.233</ci_lower_limit>
            <ci_upper_limit>0.365</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.302</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.236</ci_lower_limit>
            <ci_upper_limit>0.369</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.338</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.271</ci_lower_limit>
            <ci_upper_limit>0.405</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were obtained 30 minutes prior to the last am dose of study drug after six weeks of treatment . Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.053"/>
                    <measurement group_id="O2" value="0.125" spread="0.053"/>
                    <measurement group_id="O3" value="0.133" spread="0.054"/>
                    <measurement group_id="O4" value="0.141" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0163</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.024</ci_lower_limit>
            <ci_upper_limit>0.239</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0118</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.247</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.148</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.256</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Area Under Curve 12-24h (AUC 12-24h) Response After Six Weeks of Treatment</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 h and 10 min prior to am dose on the first day of treatment (baseline) and 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min relative to am dose after six weeks of treatment</time_frame>
        <population>Full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler or Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under Curve 12-24h (AUC 12-24h) Response After Six Weeks of Treatment</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed in the morning of the first treatment visit, just prior to administration of the morning dose of randomized treatment. Means are adjusted using a mixed effects model with center, treatment and period as fixed effects and patient within center as random. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>Full analysis set (FAS).</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048" spread="0.025"/>
                    <measurement group_id="O2" value="0.069" spread="0.025"/>
                    <measurement group_id="O3" value="0.072" spread="0.025"/>
                    <measurement group_id="O4" value="0.107" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.120</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.157</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with center, treatment and period as fixed effects and patients within center as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.018</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
        <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 5 mcg</title>
            <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 10 mcg</title>
            <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Form 12 mcg</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
          <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bundle branch block right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG QT prolonged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat resp. Aerolizer Inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Olo 5 mcg</title>
          <description>Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 10 mcg</title>
          <description>Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Form 12 mcg</title>
          <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Safety assessments are potentially confounded by both crossover and long washout periods
Comparisons of active groups for the 12 to 24 hr period overestimate the effect of Foradil (sleeping period causing an overestimation of AUC)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

